What do the names mean?
The names come from the consumer peptide market, not from medical nomenclature. They are shorthand for ingredient combinations, and different sellers use them differently. That is why the first question about any stack is simply: what exactly is in this vial, and how much of each?
Which ingredients are in each blend?
The table shows the combinations most commonly sold under each name, with the exact Peps RX formulation where Peps RX offers one.
| Ingredient | Wolverine | GLOW | KLOW |
|---|---|---|---|
| BPC-157 | ✓ | ✓ | ✓ |
| TB-500 | ✓ | ✓ | ✓ |
| GHK-Cu | — | ✓ | ✓ |
| KPV | — | — | ✓ |
| Peps RX formulation | BPC-157 3 mg/mL + TB-500 3 mg/mL, 5 mL vial | Not offered | BPC-157 3 mg/mL, GHK-Cu 10 mg/mL, KPV 3 mg/mL, TB-500 3 mg/mL, 5 mL vial |
Strengths are label specifications, not doses. Your prescribing clinician decides whether any treatment is appropriate and how it is used.
Why can two “KLOW” vials be different?
There is no official formula behind a stack name. One pharmacy’s KLOW can carry different amounts of each ingredient from another’s, and the ingredient identity can differ too. “TB-500”, for example, usually refers to a short synthetic fragment of thymosin beta-4, not the full protein (how TB-500 and thymosin beta-4 differ). Independent analysis of products sold online as TB-500 has found contents that did not match their descriptions.
So compare three things on the label: each ingredient’s name, its concentration per mL, and the vial volume. Our label-reading guide shows how.
What does the evidence say about each ingredient?
| Ingredient | Human evidence | Most of the evidence |
|---|---|---|
| BPC-157 | Three small uncontrolled reports: a 16-patient knee-pain chart review, a 12-patient bladder-pain pilot and a 2-person IV safety pilot. A 2025 systematic review found one clinical study among 36. | Rat studies of tendon, ligament, muscle and gut injury |
| TB-500 | None identified for the fragment itself. FDA reports no human exposure data. | Laboratory and animal work, much of it on full-length thymosin beta-4 |
| GHK-Cu | Small studies of topical skincare products. FDA describes limited human data for injectable routes. | Laboratory and topical cosmetic research |
| KPV | FDA has not identified any human exposure data. | Cell and mouse models of colitis |
No published study has tested Wolverine, GLOW or KLOW as a combination in people. Claims that a blend works “synergistically” are a hypothesis, not a finding.
What safety questions remain?
For every ingredient in these blends, FDA’s published safety review notes a potential risk of immune reactions (immunogenicity) and limited or absent human safety data.
What does a clinician review involve?
At Peps RX, a licensed clinician reviews your intake, health history and medications and decides whether any treatment is appropriate. A blend is not automatically a better choice than a single ingredient, and sometimes neither is the right answer. Useful questions to bring:
- What is causing the symptoms I want to address, and what established treatments should come first?
- Why a blend rather than one ingredient?
- What is known about the safety of each ingredient, and of injecting them together?